All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

promethazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2286	60-87-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: promethazine diphergan proazamine prometazin protazine promethazine hydrochloride promethazine HCl	A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals. Molecular weight: 284.42 Formula: C17H20N2S CLOGP: 4.60 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 6.48 ALOGS: -4.07 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
25	mg	O
25	mg	P
25	mg	R

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	2 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	5.03 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	25 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	14 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	14 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.09 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	14 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	100 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
March 29, 1951	FDA	DELCOR ASSET CORP

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intentional self-injury	6783.21	10.44	2029	65012	23658	63398323
Intentional overdose	5402.75	10.44	2245	64796	71907	63350074
Akathisia	541.15	10.44	240	66801	8906	63413075
Tachycardia	465.60	10.44	598	66443	117558	63304423
Depressed level of consciousness	384.41	10.44	397	66644	61681	63360300
Cholecystitis chronic	310.24	10.44	171	66870	10190	63411791
Drug ineffective	281.14	10.44	420	66621	1044345	62377636
Mydriasis	279.64	10.44	168	66873	11788	63410193
Contraindicated product administered	210.00	10.44	4	67037	217644	63204337
Anxiety	198.18	10.44	591	66450	216950	63205031
Synovitis	167.27	10.44	7	67034	186911	63235070
Glossodynia	149.74	10.44	10	67031	178866	63243115
Hand deformity	149.62	10.44	4	67037	159453	63262528
Drug intolerance	147.21	10.44	71	66970	308590	63113391
Treatment failure	145.79	10.44	19	67022	199024	63222957
Hallucination	142.67	10.44	228	66813	54589	63367392
Somnolence	141.86	10.44	463	66578	178222	63243759
Joint swelling	133.95	10.44	91	66950	327575	63094406
Arthropathy	131.68	10.44	42	66999	234750	63187231
Agitation	120.56	10.44	222	66819	59535	63362446
Off label use	118.88	10.44	344	66697	674118	62747863
Poisoning	117.65	10.44	105	66936	13595	63408386
Systemic lupus erythematosus	114.27	10.44	39	67002	208879	63213102
Pericarditis	111.15	10.44	7	67034	131572	63290409
Rheumatoid arthritis	108.44	10.44	67	66974	253752	63168229
Therapeutic product effect decreased	102.34	10.44	38	67003	193149	63228832
Biliary dyskinesia	101.33	10.44	52	66989	2677	63419304
Emotional distress	98.20	10.44	145	66896	32404	63389577
Gallbladder disorder	96.35	10.44	109	66932	18733	63403248
Abdominal discomfort	95.68	10.44	119	66922	320766	63101215
Vomiting	92.93	10.44	950	66091	558667	62863314
Suicide attempt	92.47	10.44	201	66840	60717	63361264
Wound	90.09	10.44	30	67011	163233	63258748
Sinus tachycardia	89.42	10.44	119	66922	24149	63397832
Product use issue	86.41	10.44	64	66977	220456	63201525
Gallbladder injury	86.27	10.44	38	67003	1385	63420596
Hepatic enzyme increased	85.57	10.44	54	66987	202274	63219707
Alopecia	80.45	10.44	146	66895	337390	63084591
Toxicity to various agents	79.96	10.44	490	66551	246760	63175221
Helicobacter infection	78.16	10.44	5	67036	92780	63329201
Infusion related reaction	77.48	10.44	87	66954	245434	63176547
Cholelithiasis	72.52	10.44	150	66891	43775	63378206
Migraine	71.57	10.44	256	66785	103090	63318891
Rash	69.77	10.44	330	66711	560541	62861440
Drug abuse	68.70	10.44	200	66841	72318	63349663
Respiratory arrest	67.99	10.44	123	66918	32522	63389459
Nasopharyngitis	67.97	10.44	102	66939	254155	63167826
Incoherent	65.19	10.44	47	66994	4483	63417498
Injury	64.63	10.44	197	66844	73050	63348931
Accidental overdose	60.68	10.44	97	66944	23212	63398769
Arthralgia	59.80	10.44	355	66686	569355	62852626
Loss of consciousness	58.82	10.44	264	66777	117857	63304124
Therapeutic product effect incomplete	57.67	10.44	30	67011	125026	63296955
Snoring	56.85	10.44	42	66999	4160	63417821
Peripheral swelling	56.47	10.44	123	66918	265819	63156162
Lethargy	54.52	10.44	156	66885	55851	63366130
Muscle twitching	54.18	10.44	84	66957	19584	63402397
Folliculitis	53.19	10.44	6	67035	70311	63351670
Swelling	53.15	10.44	134	66907	275244	63146737
Hypersensitivity	52.28	10.44	148	66893	292537	63129444
Impaired healing	51.27	10.44	22	67019	102520	63319461
C-reactive protein increased	51.19	10.44	18	67023	94689	63327292
Lower respiratory tract infection	49.76	10.44	40	67001	132267	63289714
Dependence	48.08	10.44	29	67012	2048	63419933
Formication	47.35	10.44	38	67003	4253	63417728
Nausea	47.18	10.44	1207	65834	853264	62568717
Discomfort	46.81	10.44	65	66976	167309	63254672
Serotonin syndrome	46.23	10.44	97	66944	28585	63393396
Deep vein thrombosis	46.08	10.44	193	66848	83607	63338374
Pulmonary haemorrhage neonatal	45.76	10.44	10	67031	26	63421955
Opisthotonus	44.39	10.44	16	67025	340	63421641
Suicidal ideation	44.37	10.44	156	66885	62265	63359716
General physical health deterioration	43.69	10.44	92	66949	201310	63220671
Mobility decreased	42.67	10.44	39	67002	121120	63300861
Cardiac arrest	42.48	10.44	202	66839	92343	63329638
Hereditary angioedema	40.80	10.44	45	66996	7517	63414464
Abdominal pain	39.71	10.44	479	66562	292977	63129004
Maternal exposure during pregnancy	39.48	10.44	111	66930	219951	63202030
Accidental death	39.18	10.44	25	67016	1951	63420030
Drug abuser	39.06	10.44	29	67012	2894	63419087
Pupillary reflex impaired	38.37	10.44	25	67016	2022	63419959
Drug hypersensitivity	38.14	10.44	498	66543	310189	63111792
Completed suicide	37.54	10.44	273	66768	145400	63276581
Mental status changes	37.28	10.44	109	66932	39490	63382491
Dysarthria	35.93	10.44	113	66928	42598	63379383
Congenital tricuspid valve incompetence	35.42	10.44	10	67031	92	63421889
Depression	33.58	10.44	336	66705	196156	63225825
Electrocardiogram QRS complex shortened	33.28	10.44	14	67027	455	63421526
Neonatal hypotension	32.36	10.44	10	67031	129	63421852
Liver injury	31.86	10.44	12	67029	60508	63361473
Psoriatic arthropathy	31.58	10.44	30	67011	91490	63330491
Hip arthroplasty	31.57	10.44	6	67035	47640	63374341
Drug screen positive	31.52	10.44	28	67013	3601	63418380
Seizure	31.03	10.44	243	66798	132391	63289590
Cholecystitis	30.83	10.44	57	66984	15320	63406661
Musculoskeletal stiffness	30.31	10.44	97	66944	184521	63237460
Product use in unapproved indication	30.17	10.44	93	66948	178987	63242994
Fear	29.81	10.44	57	66984	15709	63406272
Poor feeding infant	29.49	10.44	12	67029	358	63421623
Dehydration	29.40	10.44	296	66745	173058	63248923
Blister	29.24	10.44	58	66983	129756	63292225
Cardiac failure	28.73	10.44	31	67010	89111	63332870
Gallbladder hypofunction	27.37	10.44	13	67028	565	63421416
Intentional product use issue	27.23	10.44	59	66982	127833	63294148
Newborn persistent pulmonary hypertension	27.21	10.44	10	67031	225	63421756
Paranoia	26.90	10.44	46	66995	11633	63410348
Pulmonary embolism	26.87	10.44	213	66828	116471	63305510
Ill-defined disorder	26.83	10.44	28	67013	81727	63340254
Stomatitis	26.35	10.44	68	66973	138657	63283324
Gallbladder cholesterolosis	26.06	10.44	14	67027	792	63421189
Biliary colic	25.79	10.44	25	67016	3592	63418389
Impaired gastric emptying	25.53	10.44	42	66999	10290	63411691
Drug reaction with eosinophilia and systemic symptoms	25.31	10.44	3	67038	33833	63388148
Respiratory disorder neonatal	25.30	10.44	16	67025	1229	63420752
Gastrointestinal disorder	25.18	10.44	64	66977	131175	63290806
Neonatal respiratory failure	25.07	10.44	10	67031	283	63421698
Anhedonia	24.98	10.44	43	66998	10931	63411050
Restlessness	24.84	10.44	78	66963	29375	63392606
Exposure via ingestion	24.39	10.44	22	67019	2887	63419094
Red blood cell sedimentation rate increased	24.38	10.44	8	67033	43974	63378007
Infection	24.37	10.44	142	66899	229031	63192950
Tremor	23.98	10.44	229	66812	132010	63289971
Illness anxiety disorder	23.97	10.44	8	67033	134	63421847
Tardive dyskinesia	22.98	10.44	36	67005	8466	63413515
Atrial septal defect	22.51	10.44	32	67009	6906	63415075
Pulmonary fibrosis	22.50	10.44	7	67034	39802	63382179
Cardio-respiratory arrest	22.02	10.44	123	66918	59836	63362145
Therapeutic response decreased	21.42	10.44	20	67021	61505	63360476
Electrocardiogram QT prolonged	21.13	10.44	121	66920	59409	63362572
Drug withdrawal syndrome	21.10	10.44	70	66971	27124	63394857
Miosis	21.09	10.44	32	67009	7321	63414660
Cholesterosis	20.84	10.44	10	67031	445	63421536
Illness	20.31	10.44	104	66937	48955	63373026
Hyperreflexia	20.19	10.44	28	67013	5906	63416075
Arthritis	19.66	10.44	60	66981	115861	63306120
Condition aggravated	19.51	10.44	303	66738	401914	63020067
Mental disorder	19.48	10.44	66	66975	25853	63396128
Irritable bowel syndrome	19.27	10.44	36	67005	82376	63339605
Coma blister	19.24	10.44	7	67034	153	63421828
Unresponsive to stimuli	18.67	10.44	78	66963	33738	63388243
Knee arthroplasty	18.43	10.44	18	67023	54188	63367793
Differential white blood cell count abnormal	18.26	10.44	11	67030	775	63421206
Blood pressure fluctuation	17.41	10.44	14	67027	46303	63375678
Cholecystectomy	17.08	10.44	36	67005	10641	63411340
Renal impairment	17.01	10.44	43	66998	88312	63333669
Therapy non-responder	17.01	10.44	34	67007	75867	63346114
Cholestasis	16.95	10.44	5	67036	29429	63392552
Ventricular septal defect	16.95	10.44	22	67019	4356	63417625
Aggression	16.93	10.44	59	66982	23439	63398542
Type 2 diabetes mellitus	16.67	10.44	26	67015	63842	63358139
Device expulsion	16.66	10.44	8	67033	34914	63387067
Blood cholesterol increased	16.42	10.44	48	66993	93984	63327997
Fatigue	16.39	10.44	1117	65924	886911	62535070
Cough	16.12	10.44	215	66826	292528	63129453
Intestinal obstruction	16.07	10.44	70	66971	30829	63391152
Loss of personal independence in daily activities	16.04	10.44	51	66990	97239	63324742
Pupil fixed	15.80	10.44	14	67027	1795	63420186
Cyanosis neonatal	15.79	10.44	8	67033	401	63421580
Jaw clicking	15.52	10.44	4	67037	25	63421956
Attention-seeking behaviour	15.49	10.44	5	67036	75	63421906
Fear of disease	15.12	10.44	12	67029	1322	63420659
pH body fluid increased	15.03	10.44	3	67038	4	63421977
Overdose	14.73	10.44	186	66855	114892	63307089
Vasoplegia syndrome	14.54	10.44	13	67028	1686	63420295
Sitting disability	14.47	10.44	7	67034	317	63421664
Melaena	14.42	10.44	7	67034	30358	63391623
Inflammation	14.37	10.44	42	66999	82231	63339750
Neutropenia	14.35	10.44	117	66924	174888	63247093
Long QT syndrome congenital	14.16	10.44	5	67036	100	63421881
Drug-induced liver injury	14.09	10.44	13	67028	40209	63381772
Respiratory rate decreased	14.05	10.44	18	67023	3517	63418464
Base excess increased	14.05	10.44	4	67037	38	63421943
Psychotic disorder	13.95	10.44	59	66982	25653	63396328
Pancreatitis chronic	13.78	10.44	15	67026	2469	63419512
Adverse event	13.70	10.44	32	67009	67527	63354454
Finger amputation	13.44	10.44	8	67033	551	63421430
Musculoskeletal pain	13.44	10.44	51	66990	92226	63329755
Wrong patient received product	13.43	10.44	14	67027	2193	63419788
Pre-existing condition improved	13.42	10.44	28	67013	8216	63413765
Acute lung injury	13.41	10.44	12	67029	1559	63420422
Nephrolithiasis	13.40	10.44	83	66958	41901	63380080
Blastocystis infection	13.29	10.44	4	67037	47	63421934
Respiratory rate increased	13.26	10.44	38	67003	13610	63408371
Small intestinal obstruction	13.17	10.44	46	66995	18291	63403690
Cytomegalovirus infection	13.13	10.44	3	67038	20949	63401032
Suicidal behaviour	13.04	10.44	15	67026	2624	63419357
Drug resistance	13.02	10.44	4	67037	22929	63399052
Uterine perforation	12.95	10.44	25	67016	6938	63415043
Prolonged rupture of membranes	12.92	10.44	4	67037	52	63421929
Patent ductus arteriosus	12.91	10.44	19	67022	4231	63417750
Postpartum haemorrhage	12.84	10.44	13	67028	1968	63420013
Ventricular extrasystoles	12.80	10.44	34	67007	11653	63410328
Blood potassium decreased	12.74	10.44	82	66959	41944	63380037
Insurance issue	12.66	10.44	23	67018	6098	63415883
Hepatitis	12.64	10.44	14	67027	39774	63382207
Jugular vein thrombosis	12.59	10.44	16	67025	3102	63418879
Neuroleptic malignant syndrome	12.13	10.44	34	67007	12022	63409959
Obsessive-compulsive disorder	12.11	10.44	18	67023	4042	63417939
Constipation	12.07	10.44	317	66724	224626	63197355
Hypophagia	12.06	10.44	65	66976	31194	63390787
Hyperkinetic heart syndrome	12.04	10.44	3	67038	16	63421965
Neonatal tachycardia	12.04	10.44	3	67038	16	63421965
Panic attack	11.93	10.44	51	66990	22280	63399701
Activated partial thromboplastin time prolonged	11.92	10.44	24	67017	6869	63415112
Osteoporosis	11.75	10.44	27	67014	57311	63364670
Retching	11.63	10.44	38	67003	14607	63407374
Malnutrition	11.53	10.44	39	67002	15259	63406722
Arm amputation	11.47	10.44	3	67038	20	63421961
Weight increased	11.46	10.44	200	66841	260592	63161389
Scar	11.16	10.44	36	67005	13746	63408235
Cholecystitis acute	11.12	10.44	26	67015	8234	63413747
Slow response to stimuli	11.09	10.44	9	67032	1023	63420958
Fallot's tetralogy	11.01	10.44	4	67037	87	63421894
Adverse drug reaction	11.01	10.44	45	66996	79669	63342312
Infusion site pain	11.00	10.44	41	67000	16828	63405153
Lentigo	11.00	10.44	6	67035	350	63421631
Withdrawal syndrome	10.94	10.44	46	66995	19951	63402030
Appetite disorder	10.92	10.44	24	67017	7297	63414684
Transverse sinus thrombosis	10.91	10.44	7	67034	551	63421430
Visceral oedema	10.89	10.44	3	67038	25	63421956
Prescribed overdose	10.86	10.44	12	67029	34141	63387840
Catatonia	10.79	10.44	18	67023	4459	63417522
Patient uncooperative	10.76	10.44	5	67036	207	63421774
Pickwickian syndrome	10.74	10.44	6	67035	367	63421614
Radial pulse abnormal	10.68	10.44	3	67038	27	63421954
Hepatocellular injury	10.64	10.44	8	67033	27373	63394608
Intestinal ischaemia	10.60	10.44	24	67017	7444	63414537

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intentional self-injury	2129.99	12.14	662	24800	13109	34918360
Intentional overdose	1659.05	12.14	749	24713	42925	34888544
Akathisia	163.92	12.14	91	25371	8018	34923451
Depressed level of consciousness	116.99	12.14	150	25312	42691	34888778
Respiratory arrest	90.77	12.14	107	25355	27936	34903533
Tachycardia	89.04	12.14	193	25269	84579	34846890
Sinus tachycardia	71.24	12.14	75	25387	17285	34914184
Drug ineffective	67.14	12.14	146	25316	456605	34474864
Off label use	64.22	12.14	131	25331	419393	34512076
Somnolence	62.15	12.14	200	25262	110916	34820553
Mydriasis	56.80	12.14	45	25417	7192	34924277
Dystonia	53.93	12.14	52	25410	10793	34920676
Vomiting	51.39	12.14	332	25130	247289	34684180
Poisoning	50.48	12.14	53	25409	12173	34919296
Agitation	48.46	12.14	120	25342	57279	34874190
Dysarthria	39.71	12.14	82	25380	34700	34896769
Hallucination	38.64	12.14	103	25359	51395	34880074
Loss of consciousness	37.62	12.14	139	25323	82528	34848941
Exposure during pregnancy	37.36	12.14	39	25423	8895	34922574
Neuroleptic malignant syndrome	35.73	12.14	54	25408	17880	34913589
Anxiety	31.76	12.14	150	25312	99278	34832191
Consciousness fluctuating	31.56	12.14	16	25446	1171	34930298
Interstitial lung disease	31.32	12.14	5	25457	65277	34866192
Cardio-respiratory arrest	30.41	12.14	99	25363	55174	34876295
Autoscopy	29.97	12.14	10	25452	247	34931222
Dehydration	29.20	12.14	178	25284	129791	34801678
Toxicity to various agents	27.54	12.14	244	25218	200118	34731351
Lethargy	26.65	12.14	78	25384	41044	34890425
Cardiac arrest	25.04	12.14	137	25325	96022	34835447
Failure to thrive	24.85	12.14	31	25431	8570	34922899
General symptom	23.75	12.14	12	25450	872	34930597
Dextrocardia	23.66	12.14	7	25455	115	34931354
Foetal alcohol syndrome	22.46	12.14	7	25455	138	34931331
Condition aggravated	22.28	12.14	69	25393	192127	34739342
Overdose	21.25	12.14	126	25336	90933	34840536
Opisthotonus	20.82	12.14	9	25453	458	34931011
Drug withdrawal syndrome	20.59	12.14	45	25417	19789	34911680
Confusional state	20.53	12.14	177	25285	143983	34787486
Unresponsive to stimuli	20.52	12.14	55	25407	27514	34903955
Atrial septal defect	20.33	12.14	26	25436	7366	34924103
Nasopharyngitis	20.23	12.14	13	25449	69955	34861514
Psychotic disorder	19.44	12.14	50	25412	24402	34907067
Respiratory depression	19.36	12.14	39	25423	16206	34915263
Completed suicide	18.69	12.14	129	25333	98039	34833430
Acute kidney injury	18.59	12.14	138	25324	304850	34626619
Drug hypersensitivity	18.51	12.14	111	25351	80418	34851051
Patent ductus arteriosus	18.43	12.14	17	25445	3337	34928132
Cardiomegaly	18.33	12.14	37	25425	15401	34916068
Nausea	18.26	12.14	348	25114	339560	34591909
Therapeutic product effect incomplete	18.21	12.14	7	25455	50534	34880935
Hepatic ischaemia	18.18	12.14	8	25454	425	34931044
Exposure via ingestion	18.06	12.14	14	25448	2167	34929302
Product use in unapproved indication	17.60	12.14	37	25425	117462	34814007
Accidental overdose	16.86	12.14	42	25420	20098	34911371
Fallot's tetralogy	16.73	12.14	6	25456	185	34931284
Obsessive thoughts	16.71	12.14	9	25453	746	34930723
Extrapyramidal disorder	16.66	12.14	32	25430	12848	34918621
Tracheobronchitis	16.55	12.14	10	25452	1031	34930438
Psychomotor hyperactivity	16.43	12.14	27	25435	9595	34921874
Upper respiratory tract irritation	15.25	12.14	4	25458	41	34931428
Skin swelling	14.08	12.14	10	25452	1355	34930114
Foetal exposure during pregnancy	14.04	12.14	60	25402	38041	34893428
Congenital aortic valve stenosis	14.00	12.14	5	25457	152	34931317
Sedation	13.75	12.14	40	25422	20966	34910503
Pupil fixed	13.71	12.14	11	25451	1790	34929679
Intentional product use issue	13.69	12.14	14	25448	59802	34871667
Fatigue	13.44	12.14	359	25103	370294	34561175
Restlessness	13.43	12.14	45	25417	25437	34906032
Multiple organ dysfunction syndrome	13.33	12.14	22	25440	76544	34854925
Aggression	13.32	12.14	60	25402	38904	34892565
Gallbladder enlargement	13.22	12.14	9	25453	1139	34930330
Mucosal haemorrhage	12.53	12.14	10	25452	1615	34929854
Ventricular septal defect	12.49	12.14	15	25447	3986	34927483
Angioedema	12.16	12.14	6	25456	37368	34894101

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intentional self-injury	5502.25	10.31	1743	67326	30676	79644643
Intentional overdose	4203.96	10.31	1975	67094	103985	79571334
Akathisia	575.58	10.31	264	68805	12995	79662324
Tachycardia	377.00	10.31	604	68465	177164	79498155
Depressed level of consciousness	343.55	10.31	421	68648	96231	79579088
Cholecystitis chronic	287.91	10.31	150	68919	9756	79665563
Mydriasis	226.51	10.31	158	68911	17485	79657834
Drug ineffective	206.87	10.31	390	68679	1080523	78594796
Anxiety	174.56	10.31	542	68527	247970	79427349
Poisoning	174.35	10.31	157	68912	25115	79650204
Respiratory arrest	173.32	10.31	231	68838	57319	79618000
Off label use	172.74	10.31	328	68741	906887	78768432
Hallucination	136.55	10.31	257	68812	85488	79589831
Somnolence	129.58	10.31	478	68591	238503	79436816
Vomiting	123.48	10.31	991	68078	664837	79010482
Synovitis	116.35	10.31	3	69066	150731	79524588
Agitation	114.23	10.31	261	68808	99454	79575865
Toxicity to various agents	109.35	10.31	681	68388	420859	79254460
Biliary dyskinesia	108.30	10.31	50	69019	2495	79672824
Sinus tachycardia	107.82	10.31	146	68923	36762	79638557
Gallbladder injury	95.60	10.31	37	69032	1184	79674135
Emotional distress	94.54	10.31	143	68926	39826	79635493
Gallbladder disorder	93.69	10.31	99	68970	19241	79656078
Suicide attempt	90.50	10.31	213	68856	82719	79592600
Drug intolerance	83.44	10.31	64	69005	264055	79411264
Contraindicated product administered	80.09	10.31	19	69050	157519	79517800
Hand deformity	76.86	10.31	3	69066	103916	79571403
Cardiac arrest	76.84	10.31	324	68745	171772	79503547
Joint swelling	74.59	10.31	84	68985	288562	79386757
Treatment failure	73.21	10.31	28	69041	170458	79504861
Drug abuse	73.18	10.31	307	68762	162384	79512935
Injury	71.83	10.31	187	68882	77309	79598010
Rheumatoid arthritis	70.43	10.31	47	69022	208423	79466896
Completed suicide	69.29	10.31	406	68663	245361	79429958
Nasopharyngitis	67.67	10.31	72	68997	253809	79421510
Pericarditis	65.43	10.31	7	69062	104229	79571090
Accidental overdose	63.43	10.31	119	68950	39462	79635857
Opisthotonus	61.36	10.31	23	69046	673	79674646
Drug hypersensitivity	61.30	10.31	456	68613	298460	79376859
Arthropathy	61.09	10.31	39	69030	177072	79498247
Lethargy	59.45	10.31	180	68889	81112	79594207
Loss of consciousness	56.40	10.31	291	68778	167652	79507667
Serotonin syndrome	56.19	10.31	122	68947	44905	79630414
Nausea	56.13	10.31	1150	67919	956046	78719273
Therapeutic product effect decreased	53.93	10.31	38	69031	163825	79511494
Cholelithiasis	52.87	10.31	131	68938	52533	79622786
Glossodynia	51.46	10.31	13	69056	103324	79571995
Drug abuser	50.89	10.31	42	69027	5971	79669348
Cardio-respiratory arrest	50.52	10.31	207	68862	108303	79567016
Dysarthria	48.76	10.31	149	68920	67473	79607846
Dystonia	47.01	10.31	74	68995	21325	79653994
Arthralgia	45.65	10.31	299	68770	571504	79103815
Systemic lupus erythematosus	45.57	10.31	24	69045	121125	79554194
Hepatic enzyme increased	45.15	10.31	55	69014	182555	79492764
C-reactive protein increased	45.05	10.31	28	69041	128999	79546320
Dependence	44.09	10.31	27	69042	2395	79672924
Peripheral swelling	43.92	10.31	106	68963	269511	79405808
Incoherent	43.86	10.31	43	69026	7649	79667670
Therapeutic product effect incomplete	43.84	10.31	35	69034	141610	79533709
Exposure via ingestion	43.50	10.31	36	69033	5138	79670181
Migraine	43.20	10.31	170	68899	87323	79587996
Product use in unapproved indication	42.73	10.31	96	68973	250263	79425056
Formication	42.33	10.31	35	69034	4988	79670331
Drug withdrawal syndrome	42.10	10.31	93	68976	34625	79640694
Dehydration	41.79	10.31	362	68707	247825	79427494
Mental status changes	41.42	10.31	140	68929	66819	79608500
Snoring	39.21	10.31	35	69034	5531	79669788
Muscle twitching	39.11	10.31	74	68995	24690	79650629
Intentional product use issue	38.46	10.31	45	69024	152067	79523252
Pupillary reflex impaired	38.36	10.31	28	69041	3325	79671994
Helicobacter infection	38.31	10.31	7	69062	69697	79605622
Impaired healing	38.28	10.31	14	69055	87641	79587678
Neuroleptic malignant syndrome	38.25	10.31	78	68991	27481	79647838
Deep vein thrombosis	38.16	10.31	206	68863	120713	79554606
Abdominal discomfort	36.69	10.31	104	68965	250623	79424696
General physical health deterioration	36.12	10.31	120	68949	275118	79400201
Cardiac failure	33.85	10.31	51	69018	154791	79520528
Acute kidney injury	32.72	10.31	290	68779	519114	79156205
Product use issue	32.21	10.31	85	68984	209737	79465582
Mobility decreased	32.13	10.31	35	69034	122140	79553179
Wound	32.00	10.31	32	69037	116147	79559172
Overdose	31.68	10.31	270	68799	183936	79491383
Unresponsive to stimuli	31.35	10.31	113	68956	55675	79619644
Drug screen positive	31.09	10.31	32	69037	6031	79669288
Abdominal pain	30.78	10.31	491	68578	389078	79286241
Hereditary angioedema	30.74	10.31	30	69039	5305	79670014
Condition aggravated	30.60	10.31	282	68787	500842	79174477
Alopecia	30.26	10.31	101	68968	231254	79444065
Interstitial lung disease	29.90	10.31	32	69037	112568	79562751
Restlessness	29.45	10.31	98	68971	46394	79628925
Hypersensitivity	29.39	10.31	122	68947	262117	79413202
Rash	29.36	10.31	340	68729	578018	79097301
Illness anxiety disorder	28.12	10.31	10	69059	251	79675068
Folliculitis	27.51	10.31	7	69062	55373	79619946
Depression	27.50	10.31	298	68771	216492	79458827
Electrocardiogram QRS complex shortened	26.94	10.31	13	69056	717	79674602
Lower respiratory tract infection	26.88	10.31	44	69025	129176	79546143
Accidental death	26.37	10.31	25	69044	4266	79671053
Drug resistance	26.07	10.31	3	69066	42210	79633109
Fatigue	26.00	10.31	1017	68052	928710	78746609
Inflammation	25.61	10.31	26	69043	93727	79581592
Infusion related reaction	25.24	10.31	108	68961	230129	79445190
Cholestasis	25.10	10.31	7	69062	52102	79623217
Suicidal ideation	24.72	10.31	131	68938	76209	79599110
Pupil fixed	24.28	10.31	22	69047	3544	79671775
Gallbladder hypofunction	24.07	10.31	11	69058	536	79674783
Seizure	23.68	10.31	259	68810	188575	79486744
Stomatitis	23.64	10.31	58	69011	146699	79528620
Tremor	23.54	10.31	238	68831	169845	79505474
Cholecystectomy	22.66	10.31	34	69035	9398	79665921
Tardive dyskinesia	22.45	10.31	36	69033	10535	79664784
Psychotic disorder	21.70	10.31	82	68987	41320	79633999
Impaired gastric emptying	21.64	10.31	35	69034	10318	79665001
Fear	21.34	10.31	54	69015	21932	79653387
Paranoia	21.28	10.31	50	69019	19382	79655937
Cholesterosis	21.20	10.31	9	69060	367	79674952
Pulmonary fibrosis	21.11	10.31	6	69063	44106	79631213
Drug reaction with eosinophilia and systemic symptoms	20.99	10.31	15	69054	64229	79611090
Infection	20.99	10.31	123	68946	241589	79433730
Cholecystitis	20.98	10.31	54	69015	22158	79653161
Pulmonary embolism	20.86	10.31	234	68835	171420	79503899
Osteonecrosis of jaw	20.46	10.31	6	69063	43220	79632099
Arthritis	20.45	10.31	43	69026	114837	79560482
Pain	20.37	10.31	773	68296	703029	78972290
Loss of personal independence in daily activities	20.35	10.31	36	69033	102544	79572775
Electrocardiogram QT prolonged	20.28	10.31	141	68928	90245	79585074
Blood pressure fluctuation	20.26	10.31	17	69052	67128	79608191
Renal impairment	19.20	10.31	71	68998	157712	79517607
Red blood cell sedimentation rate increased	18.97	10.31	8	69061	45934	79629385
Miosis	18.81	10.31	42	69027	15747	79659572
Psoriatic arthropathy	18.73	10.31	24	69045	77975	79597344
Pancytopenia	18.62	10.31	77	68992	165668	79509651
Hyperkalaemia	18.59	10.31	45	69024	114353	79560966
Hepatocellular injury	18.53	10.31	9	69060	47584	79627735
Uterine perforation	18.50	10.31	25	69044	6278	79669041
Hepatitis	18.22	10.31	13	69056	55714	79619605
Psychomotor hyperactivity	18.07	10.31	43	69026	16806	79658513
Coma blister	17.80	10.31	7	69062	234	79675085
Melaena	17.66	10.31	16	69053	60874	79614445
Aggression	17.57	10.31	89	68980	50869	79624450
Bradycardia	17.15	10.31	60	69009	135497	79539822
Anhedonia	17.05	10.31	39	69030	14859	79660460
Respiratory rate increased	16.90	10.31	49	69020	21551	79653768
Musculoskeletal stiffness	16.87	10.31	86	68983	174922	79500397
Drug dependence	16.82	10.31	75	68994	40694	79634625
Cytomegalovirus infection	16.70	10.31	8	69061	42636	79632683
Angioedema	16.65	10.31	25	69044	76010	79599309
Jaw clicking	16.59	10.31	4	69065	23	79675296
Obsessive thoughts	16.58	10.31	11	69058	1121	79674198
Gallbladder cholesterolosis	16.56	10.31	9	69060	637	79674682
Respiratory depression	16.41	10.31	57	69012	27573	79647746
Extrapyramidal disorder	16.37	10.31	50	69019	22629	79652690
Weight increased	16.08	10.31	158	68911	277228	79398091
General symptom	16.03	10.31	15	69054	2519	79672800
Finger amputation	15.96	10.31	9	69060	685	79674634
Inappropriate schedule of product administration	15.69	10.31	61	69008	133567	79541752
Therapeutic response decreased	15.61	10.31	21	69048	66832	79608487
Cough	15.48	10.31	224	68845	366565	79308754
Reversible cerebral vasoconstriction syndrome	15.43	10.31	16	69053	3041	79672278
Chest pain	15.37	10.31	336	68733	281968	79393351
Biliary colic	15.27	10.31	18	69051	3944	79671375
Hip arthroplasty	15.13	10.31	6	69063	35750	79639569
Infusion site pain	15.01	10.31	36	69033	14140	79661179
Heart rate decreased	14.56	10.31	24	69045	70292	79605027
Pulmonary congestion	14.47	10.31	54	69015	27046	79648273
Discomfort	14.33	10.31	58	69011	125559	79549760
Toxic epidermal necrolysis	13.81	10.31	11	69058	44570	79630749
Prolonged rupture of membranes	13.77	10.31	4	69065	51	79675268
Blood pressure systolic increased	13.75	10.31	23	69046	66963	79608356
Fall	13.62	10.31	320	68749	487309	79188010
Gas gangrene	13.51	10.31	6	69063	273	79675046
Arm amputation	13.45	10.31	5	69064	143	79675176
Jugular vein thrombosis	13.32	10.31	18	69051	4520	79670799
Ill-defined disorder	13.17	10.31	23	69046	65852	79609467
Long QT syndrome congenital	13.16	10.31	5	69064	152	79675167
Lymphopenia	13.14	10.31	5	69064	30552	79644767
Intentional product misuse	13.08	10.31	133	68936	95032	79580287
Pneumocystis jirovecii pneumonia	12.88	10.31	6	69063	32502	79642817
Swelling	12.74	10.31	123	68946	216588	79458731
Neutropenia	12.74	10.31	174	68895	287536	79387783
Respiratory rate decreased	12.74	10.31	19	69050	5224	79670095
Differential white blood cell count abnormal	12.57	10.31	12	69057	2065	79673254
Blood potassium decreased	12.54	10.31	76	68993	46436	79628883
Musculoskeletal pain	12.49	10.31	46	69023	102308	79573011
Mental disorder	12.47	10.31	57	69012	31245	79644074
Failure to thrive	12.45	10.31	30	69039	11814	79663505
Psychological trauma	12.27	10.31	10	69059	1396	79673923
Drug eruption	12.21	10.31	12	69057	43923	79631396
Hypophagia	12.14	10.31	74	68995	45293	79630026
Drug interaction	12.00	10.31	271	68798	414912	79260407
Hyperreflexia	11.95	10.31	24	69045	8361	79666958
Mental impairment	11.94	10.31	40	69029	18996	79656323
Prostate cancer	11.91	10.31	7	69062	33261	79642058
Panic attack	11.90	10.31	47	69022	24169	79651150
Sopor	11.74	10.31	7	69062	33003	79642316
Wrong patient received product	11.60	10.31	17	69052	4601	79670718
Inadequate analgesia	11.57	10.31	17	69052	4612	79670707
Muscle spasms	11.51	10.31	214	68855	174516	79500803
Compulsions	11.35	10.31	6	69063	402	79674917
Irritable bowel syndrome	11.32	10.31	23	69046	62218	79613101
Malnutrition	11.32	10.31	44	69025	22458	79652861
Suicidal behaviour	11.28	10.31	14	69055	3233	79672086
Postpartum haemorrhage	11.18	10.31	10	69059	1585	79673734
Confusional state	11.09	10.31	357	68712	317640	79357679
Transverse sinus thrombosis	11.06	10.31	7	69062	658	79674661
Cholecystitis acute	10.99	10.31	31	69038	13420	79661899
Fear of disease	10.88	10.31	9	69060	1283	79674036
Base excess increased	10.84	10.31	4	69065	112	79675207
Osteoarthritis	10.81	10.31	39	69030	87270	79588049
Withdrawal syndrome	10.78	10.31	49	69020	26805	79648514
CSF pressure increased	10.75	10.31	5	69064	254	79675065
Osteoporosis	10.72	10.31	19	69050	54093	79621226
Knee arthroplasty	10.71	10.31	13	69056	43235	79632084
Illness	10.69	10.31	73	68996	46438	79628881
Gallbladder enlargement	10.67	10.31	10	69059	1683	79673636
Psoriasis	10.45	10.31	41	69028	89546	79585773
Angina pectoris	10.40	10.31	18	69051	51714	79623605
Schizoaffective disorder	10.39	10.31	11	69058	2141	79673178
Haemophagocytic lymphohistiocytosis	10.39	10.31	3	69066	21834	79653485

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pleural effusion	47.43	26.23	11	217	11	89553
Pulmonary haemorrhage neonatal	43.10	26.23	10	218	10	89554
Congenital tricuspid valve incompetence	32.89	26.23	10	218	46	89518

Pharmacologic Action:

Source	Code	Description
ATC	D04AA10	DERMATOLOGICALS ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. Antihistamines for topical use
ATC	R06AD02	RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Phenothiazine derivatives
ATC	R06AD52	RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Phenothiazine derivatives
ATC	V03AB05	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Antidotes
FDA CS	M0016525	Phenothiazines
MeSH PA	D018926	Anti-Allergic Agents
MeSH PA	D000982	Antipruritics
MeSH PA	D003879	Dermatologic Agents
MeSH PA	D018494	Histamine Agents
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006634	Histamine H1 Antagonists
MeSH PA	D018377	Neurotransmitter Agents
CHEBI has role	CHEBI:35717	hypnotics
CHEBI has role	CHEBI:36333	local anesthetics
CHEBI has role	CHEBI:37955	H1 receptor antagonists
CHEBI has role	CHEBI:50857	anti-allergic drugs
CHEBI has role	CHEBI:50919	antiemetico
CHEBI has role	CHEBI:59683	antipruritic drugs
CHEBI has role	CHEBI:149553	anticoronaviral drug
CHEBI has role	CHEBI:176497	geroprotectors
FDA EPC	N0000175746	Phenothiazine

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Vasomotor rhinitis	indication	8229003	DOID:4730
Nausea and vomiting	indication	16932000
General anesthesia	indication	50697003
Sedation	indication	72641008
Urticaria	indication	126485001
Seasonal allergic rhinitis	indication	367498001
Allergic conjunctivitis	indication	473460002	DOID:11204

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.19	Basic
pKa2	3.55	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	Ki	9.62		WOMBAT-PK	CHEMBL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	6.61		WOMBAT-PK
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.59		DRUG MATRIX
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	6.92		DRUG MATRIX
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		IC50	5.12		CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.38		DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.83		DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	6.77		WOMBAT-PK
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.37		DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	8.19		DRUG MATRIX
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	5.95		DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN					WOMBAT-PK
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	7.62		DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.72		DRUG MATRIX
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.94		DRUG MATRIX
Histamine H4 receptor	GPCR	Q9H3N8	HRH4_HUMAN		Ki	6.82		WOMBAT-PK
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	8.48		DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	7.92		DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	8.38		DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	8.98		DRUG MATRIX
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	8.48		DRUG MATRIX
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN		IC50	6.29		WOMBAT-PK
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	6.45		DRUG MATRIX
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		Ki	5.42		WOMBAT-PK
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	7.50		DRUG MATRIX
Cholinesterase	Enzyme	P06276	CHLE_HUMAN		Ki	7.10		WOMBAT-PK
Voltage-dependent N-type calcium channel subunit alpha-1B	Ion channel	Q00975	CAC1B_HUMAN		IC50	4.75		CHEMBL
Major prion protein	Surface antigen	P04156	PRIO_HUMAN		EC50	5.10		CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.45		CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III)	Ion channel	P35498 Q99250 Q9NY46	SCN1A_HUMAN SCN2A_HUMAN SCN3A_HUMAN		IC50	5.16		CHEMBL
FAD-linked sulfhydryl oxidase ALR	Enzyme	P55789	ALR_HUMAN		AC50	6.44		CHEMBL
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	5.86		DRUG MATRIX
Calmodulin-1	Cytosolic other	P0DP23	CALM1_HUMAN		IC50	4.22		CHEMBL
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	7.68		DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	7.10		CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	5.59		CHEMBL
Pleiotropic ABC efflux transporter of multiple drugs	Transporter		PDR5_YEAST		IC50	4.75		CHEMBL
Chloroquine resistance transporter	Transporter		CRT_PLAFA		IC50	4.07		CHEMBL
Calmodulin	Cytosolic other		CALM_BOVIN		Kd	4.30		CHEMBL

External reference:

ID	Source
4019910	VUID
N0000147995	NUI
D00480	KEGG_DRUG
58-33-3	SECONDARY_CAS_RN
4017846	VANDF
4019910	VANDF
C0033405	UMLSCUI
CHEBI:8461	CHEBI
CHEMBL1200750	ChEMBL_ID
CHEMBL251904	ChEMBL_ID
CHEMBL643	ChEMBL_ID
DB01069	DRUGBANK_ID
D011398	MESH_DESCRIPTOR_UI
4927	PUBCHEM_CID
7282	IUPHAR_LIGAND_ID
516	INN_ID
FF28EJQ494	UNII
142445	RXNORM
2141	MMSL
5367	MMSL
d00787	MMSL
001483	NDDF
004459	NDDF
14905007	SNOMEDCT_US
372871004	SNOMEDCT_US
8372007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE	HUMAN PRESCRIPTION DRUG LABEL	2	0121-0547	SYRUP	6.25 mg	ORAL	ANDA	30 sections
Promethazine VC with Codeine Oral Solution	HUMAN PRESCRIPTION DRUG LABEL	3	0121-0925	SOLUTION	6.25 mg	ORAL	ANDA	29 sections
Promethazine VC with Codeine Oral Solution	HUMAN PRESCRIPTION DRUG LABEL	3	0121-0925	SOLUTION	6.25 mg	ORAL	ANDA	29 sections
Promethazine VC	HUMAN PRESCRIPTION DRUG LABEL	2	0121-0926	SOLUTION	6.25 mg	ORAL	ANDA	25 sections
Promethazine VC	HUMAN PRESCRIPTION DRUG LABEL	2	0121-0926	SOLUTION	6.25 mg	ORAL	ANDA	25 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0927	SOLUTION	6.25 mg	ORAL	ANDA	25 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0927	SOLUTION	6.25 mg	ORAL	ANDA	25 sections
Promethazine with Codeine	HUMAN PRESCRIPTION DRUG LABEL	2	0121-0928	SOLUTION	6.25 mg	ORAL	ANDA	29 sections
PROMETHAZINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9940	INJECTION	25 mg	INTRAMUSCULAR	ANDA	12 sections
PROMETHAZINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9940	INJECTION	25 mg	INTRAMUSCULAR	ANDA	12 sections
PROMETHAZINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9940	INJECTION	25 mg	INTRAMUSCULAR	ANDA	12 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9941	INJECTION	25 mg	INTRAMUSCULAR	ANDA	12 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9941	INJECTION	25 mg	INTRAMUSCULAR	ANDA	12 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9941	INJECTION	25 mg	INTRAMUSCULAR	ANDA	12 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9942	INJECTION	50 mg	INTRAMUSCULAR	ANDA	12 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9942	INJECTION	50 mg	INTRAMUSCULAR	ANDA	12 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9942	INJECTION	50 mg	INTRAMUSCULAR	ANDA	12 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0440-5195	TABLET	25 mg	ORAL	ANDA	11 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0440-8195	TABLET	25 mg	ORAL	ANDA	12 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0591-5307	TABLET	25 mg	ORAL	ANDA	24 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0591-5319	TABLET	50 mg	ORAL	ANDA	24 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8154	TABLET	25 mg	ORAL	ANDA	21 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0641-0928	INJECTION	25 mg	INTRAMUSCULAR	ANDA	25 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0641-0928	INJECTION	25 mg	INTRAMUSCULAR	ANDA	25 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0641-0929	INJECTION	50 mg	INTRAMUSCULAR	ANDA	25 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0641-0929	INJECTION	50 mg	INTRAMUSCULAR	ANDA	25 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0641-0948	INJECTION	25 mg	INTRAMUSCULAR	ANDA	25 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0641-0948	INJECTION	25 mg	INTRAMUSCULAR	ANDA	25 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0641-0949	INJECTION	50 mg	INTRAMUSCULAR	ANDA	25 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0641-0949	INJECTION	50 mg	INTRAMUSCULAR	ANDA	25 sections